Search

Your search keyword '"Campochiaro C"' showing total 527 results

Search Constraints

Start Over You searched for: Author "Campochiaro C" Remove constraint Author: "Campochiaro C"
527 results on '"Campochiaro C"'

Search Results

1. The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis

2. Multimodal Chorioretinal Imaging in Erdheim-Chester Disease

3. POS0821 MENOPAUSE AND SYSTEMIC SCLEROSIS: THE LINK BETWEEN MENOPAUSAL AGE, DISEASE ONSET AND CLINICAL MANIFESTATIONS IN AN ANALYSIS OF THE SPRING-SIR REGISTRY

4. AB1329 COMPARATIVE EFFICACY AND SAFETY OF GLUCOCORTICOIDS, METHOTREXATE AND TOCILIZUMAB IN THE TREATMENT OF NEW-ONSET LARGE VESSEL GIANT CELL ARTERITIS

6. POS0842 PRIMARY HEART INVOLVEMENT IN SYSTEMIC SCLEROSIS: THE ROLE OF VENTRICULAR ECTOPIC BEATS AS RED FLAGS FOR ACTIVE MYOCARDIAL INFLAMMATION DETECTED AT CARDIAC MAGNETIC RESONANCE

7. Vascularite des gros vaisseaux associées aux inhibiteurs de checkpoint immunitaire : étude rétrospective multicentrique

8. OP0265 RITUXIMAB RETENTION RATE IN SYSTEMIC SCLEROSIS: A REAL-LIFE ITALIAN MULTICENTER STUDY

9. OP0225 CHANGES IN TREATMENT PATTERNS AND THEIR INFLUENCE ON THE OUTCOME OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSc-ILD) PATIENTS: AN EUSTAR ANALYSIS

10. POS0826 PREDICTORS OF RESPONSE AND LONG-TERM EFFICACY AND SAFETY OF NINTEDANIB IN SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE: DATA FROM AN ITALIAN MULTICENTRE STUDY

11. OP0073 UNRAVELING PATHOPHYSIOLOGY AND HEMATOPOIESIS OF VEXAS SYNDROME BY MULTI-OMICS ANALYSIS AND TARGETED GENE EDITING

12. POS0843 IMMUNOSUPPRESSIVE THERAPY TO TREAT NEWLY DIAGNOSED PRIMARY HEART INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: AN ITALIAN CARDIAC MAGNETIC RESONANCE BASED STUDY

14. Efficacité et tolérance des thérapies ciblées au cours du syndrome VEXAS : étude rétrospective du groupe français VEXAS sur 110 patients

15. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology

16. Immunomodulation to target biopsy-proven myocardial inflammation in genetic cardiomyopathies: a pilot report

17. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology

19. Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature

20. Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology

23. POS0948 PATTERNS OF DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS PATIENTS WITH INTERSTITIAL LUNG DISEASE

24. POS0541 INFLAMMATORY RHEUMATIC DISEASES (IRD) WITH ONSET AFTER SARS-COV-2 INFECTION OR COVID-19 VACCINATION: A COHORT STUDY FROM THE COVID-19 & ASD COLLABORATIVE STUDY GROUP

25. POS0712 WHAT IS THE OUTCOME OF PATIENTS WITH OR WITHOUT SUBCLINICAL GIANT CELL ARTERITIS IN POLYMYALGIA RHEUMATICA? PRELIMINARY DATA OF AN OBSERVATION STUDY

26. AB0431 CANAKINUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN STILL’S DISEASE AND DIFFERENCES BETWEEN THE SYSTEMIC AND THE CHRONIC-ARTICULAR COURSES: REAL-LIFE EXPERIENCE FROM THE INTERNATIONAL AIDA REGISTRY

28. POS0708 VALIDATION OF THE REVISED 2022 AMERICAN COLLEGE OF RHEUMATOLOGY/ EULAR CLASSIFICATION CRITERIA FOR TAKAYASU ARTERITIS

33. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology

34. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study

35. Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production

36. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

40. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

41. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

42. Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis

43. Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum

44. Clinical characteristics of juvenile onset systemic sclerosis patients from the juvenile scleroderma inception cohort compared to adult age juvenile-onset patients from EUSTAR. Are these differences suggesting risk for mortality?

45. NON-SURGICAL LOCAL TREATMENTS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW

46. SYSTEMIC PHARMACOLOGICAL TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW

47. SURGICAL MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW.

48. Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology

49. Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature

50. The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19

Catalog

Books, media, physical & digital resources